Neumora Therapeutics, Inc.
US ˙ NasdaqGS ˙ US6409791000

SecurityNMRA / Neumora Therapeutics, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership59,584 shares
Latest Disclosed Value $ 116,189
UBS Group AG ownership in NMRA / Neumora Therapeutics, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 59,584 shares of Neumora Therapeutics, Inc. (US:NMRA) valued at $116,189 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 94,906 shares of Neumora Therapeutics, Inc.. This represents a change in shares of -37.22% during the quarter. The current value of the position is $103,676 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (NMRA) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

NMRA / Neumora Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F NEUMORA THERAPEUTICS COM 640979100 59,584 -35,322 -37.22 116 -31.36 0.0000
2026-01-29 2025-12-31 13F NEUMORA THERAPEUTICS COM 640979100 94,906 -34,140 -26.46 170 -27.78 0.0000
2025-11-13 2025-09-30 13F NEUMORA THERAPEUTICS COM 640979100 129,046 -521,658 -80.17 235 -50.84 0.0000
2025-08-14 2025-06-30 13F NEUMORA THERAPEUTICS COM 640979100 650,704 -2,455,852 -79.05 477 -84.67 0.0001
2025-05-13 2025-03-31 13F NEUMORA THERAPEUTICS COM 640979100 3,106,556 1,864,611 150.14 3,107 -76.41 0.0006
2025-02-14 2024-12-31 13F NEUMORA THERAPEUTICS COM 640979100 1,241,945 902,274 265.63 13,165 193.38 0.0024
2024-11-14 2024-09-30 13F NEUMORA THERAPEUTICS COM 640979100 339,671 44,014 14.89 4,487 54.40 0.0010
2024-08-14 2024-06-30 13F NEUMORA THERAPEUTICS COM 640979100 295,657 270,376 1,069.48 2,906 737.46 0.0007
2024-05-13 2024-03-31 13F NEUMORA THERAPEUTICS COM 640979100 25,281 25,025 9,775.39 348 8,575.00 0.0001
2024-02-09 2023-12-31 13F NEUMORA THERAPEUTICS COM 640979100 256 256 4 0.0000
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-05-13 2025-03-31 13F NEUMORA THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-14 2024-12-31 13F NEUMORA THERAPEUTICS COM Put 12,000 127 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.